
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
Positive biomarker data in patient aged 1-3 add to consistent, robust microdystrophin and transduction levels across all treated agesPatient aged 3 years at dosing had expression level at 122.3% compared to control With a differentiated novel construct and …